Changing epidemiology of bacterial infection in neutropenic patients with cancer.

[1]  B. Oppenheim.  The changing pattern of infection in neutropenic patients. , 1998, The Journal of antimicrobial chemotherapy.

[2]  F. Alcaide,et al.  Bacteremic pneumonia in neutropenic patients with cancer: causes, empirical antibiotic therapy, and outcome. , 1998, Archives of internal medicine.

[3]  J. Lau,et al.  Efficacy of quinolone prophylaxis in neutropenic cancer patients: a meta-analysis. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  L. Young,et al.  1997 guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Infectious Diseases Society of America. , 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[5]  L. Elting,et al.  Outcomes of bacteremia in patients with cancer and neutropenia: observations from two decades of epidemiological and clinical trials. , 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[6]  F. Gudiol,et al.  Treatment of penicillin-resistant pneumococcal bacteremia in neutropenic patients with cancer. , 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[7]  A. Messori,et al.  Prophylaxis with fluoroquinolones for bacterial infections in neutropenic patients: a meta-analysis. , 1996, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[8]  F. Alcaide,et al.  In vitro activities of eight macrolide antibiotics and RP-59500 (quinupristin-dalfopristin) against viridans group streptococci isolated from blood of neutropenic cancer patients , 1996, Antimicrobial agents and chemotherapy.

[9]  K. Papadakis,et al.  Bacteremia due to Stenotrophomonas (Xanthomonas) maltophilia: a prospective, multicenter study of 91 episodes. , 1996, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[10]  D. Raveh,et al.  Nosocomial coagulase-negative staphylococcal infections in bone marrow transplantation recipients with central vein catheter. A 5-year prospective study. , 1996, Transplantation.

[11]  F. Tubau,et al.  Emergence of fluoroquinolone-resistant Escherichia coli in fecal flora of cancer patients receiving norfloxacin prophylaxis , 1996, Antimicrobial agents and chemotherapy.

[12]  J. Peyri,et al.  A papular eruption secondary to infection with Corynebacterium jeikeiwn, with histopathological features mimicking botryomycosis , 1995, The British journal of dermatology.

[13]  F. Alcaide,et al.  In vitro activities of 22 beta-lactam antibiotics against penicillin-resistant and penicillin-susceptible viridans group streptococci isolated from blood , 1995, Antimicrobial agents and chemotherapy.

[14]  P. Moreau,et al.  Viridans streptococcal bacteraemia in patients with neutropenia , 1995, The Lancet.

[15]  F. Alcaide,et al.  Bacteremia due to viridans streptococci that are highly resistant to penicillin: increase among neutropenic patients with cancer. , 1995, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[16]  R. Wenzel,et al.  Vancomycin-resistant Enterococcus faecium bacteremia: risk factors for infection. , 1995, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[17]  F. Gudiol,et al.  Life-threatening infections due to penicillin-resistant viridans streptococci , 1995 .

[18]  F. Tubau,et al.  Emergence of quinolone-resistant Escherichia coli bacteremia in neutropenic patients with cancer who have received prophylactic norfloxacin. , 1995, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[19]  M. Paesmans,et al.  Piperacillin-tazobactam plus amikacin versus ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer , 1995, Antimicrobial agents and chemotherapy.

[20]  G. Archer,et al.  Antimicrobial susceptibility of coagulase-negative staphylococci , 1994, Antimicrobial Agents and Chemotherapy.

[21]  P. Francioli,et al.  Bacteremia due to viridans streptococci in neutropenic patients: a review. , 1994, The American journal of medicine.

[22]  G. Wormser,et al.  Outbreak of vancomycin-, ampicillin-, and aminoglycoside-resistant Enterococcus faecium bacteremia in an adult oncology unit , 1994, Antimicrobial Agents and Chemotherapy.

[23]  A. Brown,et al.  The changing epidemiology of infections at cancer hospitals. , 1993, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[24]  L. Rice,et al.  Emerging antimicrobial resistance and the immunocompromised host. , 1993, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[25]  P. Pizzo,et al.  Management of fever in patients with cancer and treatment-induced neutropenia. , 1993, The New England journal of medicine.

[26]  J. Villablanca,et al.  Viridans streptococcal shock in bone marrow transplantation patients , 1993, American journal of hematology.

[27]  A. Awada,et al.  Streptococcal and enterococcal bacteremia in patients with cancer. , 1992, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[28]  L. Elting,et al.  Septicemia and shock syndrome due to viridans streptococci: a case-control study of predisposing factors. , 1992, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[29]  D. Bruckner,et al.  Beta-lactam antibiotic therapy in febrile granulocytopenic patients. A randomized trial comparing cefoperazone plus piperacillin, ceftazidime plus piperacillin, and imipenem alone. , 1991, Annals of internal medicine.

[30]  L. Elting,et al.  Bacteremia caused by Enterobacter: 15 years of experience in a cancer hospital. , 1991, Reviews of infectious diseases.

[31]  D. Classen,et al.  Streptococcus mitis sepsis in bone marrow transplant patients receiving oral antimicrobial prophylaxis. , 1990, The American journal of medicine.

[32]  D. Armstrong,et al.  Bacteremia and fungemia in patients with neoplastic disease. , 1987, The American journal of medicine.

[33]  P. Wiernik,et al.  Staphylococcus epidermidis: an increasing cause of infection in patients with granulocytopenia. , 1982, Annals of internal medicine.

[34]  W. R. Mccabe,et al.  Gram-negative bacteremia: IV. Re-evaluation of clinical features and treatment in 612 patients , 1980 .

[35]  M. Kaplan,et al.  Bacteremia and fungemia complicating neoplastic disease. A study of 364 cases. , 1977, The American journal of medicine.

[36]  G. Bodey,et al.  The Changing Spectrum of Bacterial Infections in Febrile Neutropenic Patients , 1997 .

[37]  E. Kuijper,et al.  Corynebacterium CDC group JK (Corynebacterium jeikeium) sepsis in haematological patients: a report of three cases and a systematic literature review. , 1995, Scandinavian journal of infectious diseases.

[38]  P. Francioli,et al.  Bacteremia due to viridans streptococcus in neutropenic patients with cancer: clinical spectrum and risk factors. , 1994, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[39]  M. Paesmans,et al.  Efficacy and Toxicity of Single Daily Doses of Amikacin and Ceftriaxone versus Multiple Daily Doses of Amikacin and Ceftazidime for Infection in Patients with Cancer and Granulocytopenia , 1993, Annals of Internal Medicine.

[40]  T. Calandra,et al.  Gram-positive bacteraemia in granulocytopenic cancer patients. , 1990, European journal of cancer.

[41]  W. J. Martin,et al.  Coagulase-negative staphylococcal bacteremia in patients receiving immunosuppressive therapy. , 1983, Archives of internal medicine.